March 2011

Hutchinson Technology announces FDA Clearance of the InSpectra™ StO₂ Spot Check.
Hutchinson Technology Inc. (NASDAQ: HTCH) announced that it has received 510(k) clearance of the InSpectra™ StO₂ Spot Check for from the U.S. Food and Drug Administration.  The product, which is targeted for use in emergency and critical care environments, is a cost-effective tool to rapidly assess tissue perfusion and shock. More 

November 2010

Hutchinson Technology announces CE Mark of the InSpectra™ StO₂ Spot Check.
Market launch under way in European Union.
Hutchinson Technology Inc. (NASDAQ: HTCH) announces CE Mark and market launch of the InSpectra™ StO₂ Spot Check for use as a noninvasive, cost-effective tool to rapidly assess the tissue oxygenation of patients in circulatory distress.  More